Ceralasertib Plus Durvalumab in Chinese Patients with Advanced Solid Tumors: A Nonrandomized Clinical Trial [0.03%]
西维拉塞替联合德瓦鲁单抗治疗晚期实体瘤中国患者的非随机临床试验
Yuping Sun,Jia Zhong,Huiwen Sun et al.
Yuping Sun et al.
Introduction: This phase I, multicenter, nonrandomized open-label study is the first study to investigate the safety, pharmacokinetics, and antitumor activity of ceralasertib, an oral ATR kinase inhibitor, in combination ...
Clinicians' Perspectives on the Impact of Different Attributes of Androgen Receptor Pathway Inhibitors on Prostate Cancer Treatment Preferences and Compliance in Mexico [0.03%]
墨西哥临床医生对雄激素受体途径抑制剂的不同属性对前列腺癌治疗偏好和依从性影响的观点
Mario Escobar Gómez,Ana Maria Rodríguez-Leboeuf,Selene Camargo-Correa et al.
Mario Escobar Gómez et al.
Introduction: Androgen receptor pathway inhibitors (ARPIs) are a critical prostate cancer (PC) treatment option. Previous research has suggested that the physical attributes of ARPI medications (e.g., pill formulation, pi...
A Comprehensive Mapping of Real-World Studies and Data Sources for Oncology in China: Insights into Landscape, Challenges, and Future Direction [0.03%]
中国肿瘤真实世界研究与数据资源全景式地图：现状、挑战与未来方向展望
Yaqi Jia,Yanbing Li,Siyan Zhan et al.
Yaqi Jia et al.
Introduction: Cancer remains a major public health concern in China, with approximately 2.57 million cancer-related deaths reported in 2022. Real-world studies (RWS), which leverage high-quality real-world data (RWD), can...
IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment [0.03%]
IMMPACT-MM：早期使用cilta-cel治疗后多发性骨髓瘤患者预后的启示
Sridevi Rajeeve,Saurabh P Nagar,Sabyasachi Ghosh et al.
Sridevi Rajeeve et al.
Introduction: Ciltacabtagene autoleucel (cilta-cel) has demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma (RRMM), supporting the goal of sustained minimal residual disease (MRD)...
Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape [0.03%]
新兴PD-(L)1/VEGF双特异性抗体在晚期肾细胞癌治疗领域的作用播客讲座
Brian I Rini,Benjamin Garmezy
Brian I Rini
Combinations of an immune checkpoint inhibitor (ICI) + anti-programmed cell death 1 protein (PD-1) or anti-programmed cell death ligand 1 (PD-L1) or an ICI + tyrosine kinase inhibitor (TKI; anti-vascular endothelial growth factor [VEGF]) ar...
Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): An Aggressive Disease Course and Limitations for Personalized Oncology [0.03%]
胃肠胰神经内分泌癌(GEP-NEC)：侵袭性的疾病进程和个体化肿瘤的局限性
Celine Oanæs,Herish Garresori,Dordi Lea et al.
Celine Oanæs et al.
Neuroendocrine carcinoma (NEC) is a rare, aggressive malignancy with limited treatment options and poor prognosis. We report a male patient diagnosed with a gastroenteropancreatic (GEP)-NEC with synchronous liver metastasis at the time of s...
Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL [0.03%]
初治慢性淋巴细胞白血病患者接受布鲁顿酪氨酸激酶抑制剂治疗的现实世界结局：一项基于医疗保险数据库的研究
Daniel A Ermann,Deborah M Stephens,Xiaoliang Wang et al.
Daniel A Ermann et al.
Introduction: There is a dearth of head-to-head studies comparing covalent Bruton tyrosine kinase (cBTK) inhibitors in adults with chronic lymphocytic leukemia (CLL). Real-world evidence may complement clinical trial data...
Real-World Actionability Analysis of Comprehensive Genomic Profiling Versus Single/Small-Gene Panels [0.03%]
全面基因组 profiling与单一/小规模基因检测的行动性分析
Paul Spin,Bela Bapat,Chad Moretz et al.
Paul Spin et al.
Introduction: Comprehensive genomic profiling (CGP) enables identification of patients eligible for targeted treatments, making it essential in the management of advanced cancer. This retrospective real-world study compar...
Evaluation of Drug-Drug Interactions Using Drug-PIN® in Patients Receiving Avelumab Maintenance for Advanced Urothelial Carcinoma: Evidence from the MALVA Study (Meet-URO 25) [0.03%]
MALVA研究（Meet-URO 25）：利用药物蛋白质相互作用网络评估阿维鲁单抗维持治疗晚期尿路上皮癌患者的药物相互作用的证据
Giandomenico Roviello,Mattia Alberto Di Civita,Daniele Santini et al.
Giandomenico Roviello et al.
Introduction: Polypharmacy is common in patients with advanced urothelial carcinoma (UC) receiving avelumab maintenance therapy, raising concerns about potential drug-drug interactions (DDIs). ...
Abemaciclib in HR+, HER2- Breast Cancer: A Narrative Review of the Clinical Evidence [0.03%]
阿贝西利在HR+/HER2-乳腺癌临床证据的综述分析
Miguel Martin,Alexandru Rosca,Alexandra Searles Vitko et al.
Miguel Martin et al.
Hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) breast cancer comprises approximately 70% of all breast cancer cases. In early-stage breast cancer, adjuvant endocrine therapy (ET) reduces recurrence and mor...